VisualSonics Announces Record Growth and Increased Global Demand for Micro Ultrasound Technology.TORONTO -- Company Sells 200th System and Continues To Grow at Compounded Annual Rate of 145% Over Past Three Years VisualSonics, the world's leading developer of high-resolution, ultrasound-based, in vivo in vivo /in vi·vo/ (ve´vo) [L.] within the living body. in vi·vo adj. Within a living organism. in vivo adv. micro-imaging systems, today announced record growth and increased global demand for its Vevo(TM) platform, having recently sold its 200th system. The company reached this milestone in just over three years, validating the significant demand for micro-ultrasound technology among biotechnology, pharmaceutical and medical research organizations. Starting with quarterly revenues of a few hundred thousand dollars in 2003, VisualSonics has experienced a 145% compounded annual growth rate, quickly reaching its current $24 million in annualized annualized Of or relating to a variable that has been mathematically converted to a yearly rate. Inflation and interest rates are generally annualized since it is on this basis that these two variables are ordinarily stated and compared. sales. The global market for preclinical ultrasound imaging systems is estimated to be $2.9 billion and micro-ultrasound is the fastest growing preclinical modality modality /mo·dal·i·ty/ (mo-dal´i-te) 1. a method of application of, or the employment of, any therapeutic agent, especially a physical agent. 2. in the market. VisualSonics' growth trajectory will be accelerated by the company's introduction of molecular imaging capabilities on the Vevo 770 platform. With this expanded functionality, researchers can now study molecular patterns of expression such as those associated with angiogenesis angiogenesis /an·gio·gen·e·sis/ (-jen´e-sis) vasculogenesis; development of blood vessels either in the embryo or in the form of neovascularization or revascularization. an·gi·o·gen·e·sis n. for cancer research and anti-angiogenic therapeutic studies. In addition to increased sales, VisualSonics is experiencing greater global demand for its micro-ultrasound technology. Responding to this need, VisualSonics expanded its international sales and support efforts, recently opening an office and in vivo demonstration facility in Amsterdam, The Netherlands. The company also signed an agreement with Israeli distributor, Lavi-Industrial and Medical Agencies Ltd to compliment its extensive existing network of seven distributors across Asia and the Pan Pacific. VisualSonics will continue to expand its international distribution system. "As the only commercialized high-resolution, high-frequency micro-ultrasound technology for use in preclinical research, VisualSonics' Vevo 770 is serving a global market of academic and industrial researchers who are creating new protocols and making discoveries with our platform," states Tom Little, President and CEO (1) (Chief Executive Officer) The highest individual in command of an organization. Typically the president of the company, the CEO reports to the Chairman of the Board. of VisualSonics. He continues, "With our growing reputation, recognition among customers and enhanced molecular imaging capabilities, VisualSonics is poised for substantial and continued growth, as we become a multi-product company with recurring revenue streams." VisualSonics' news of record growth and increased international demand comes a week after it announced the Vevo's enhanced functionality with molecular imaging capabilities. In January, VisualSonics also announced its quality management system has been registered as complying with the requirements of ISO (1) See ISO speed. (2) (International Organization for Standardization, Geneva, Switzerland, www.iso.ch) An organization that sets international standards, founded in 1946. The U.S. member body is ANSI. 9001:2000. About VisualSonics VisualSonics is the world's leading developer of high-resolution, ultrasound-based, in vivo micro-imaging systems designed specifically for non-invasive preclinical research. The company's enabling micro-ultrasound technology, the Vevo 770, allows researchers at the world's most prestigious pharmaceutical and biotechnology companies Top 100 Biotechnology Companies The following is a list of the top 100 biotechnology companies ranked by revenue. The first nine companies qualify for the list of the top 50 pharmaceutical companies. , hospitals and research centers to conduct genetic research, phenotypic study and drug development. Micro-ultrasound is the fastest growing preclinical imaging modality. This enabling technology is facilitating research in cardiac and vascular disease, cancer, stem cell stem cell In living organisms, an undifferentiated cell that can produce other cells that eventually make up specialized tissues and organs. There are two major types of stem cells, embryonic and adult. research and developmental biology Developmental biology A large field of investigation that includes the study of all changes associated with an organism as it progresses through the life cycle. The life cycles of all multicellular organisms exhibit many similarities. . When compared to other imaging options, only micro-ultrasound has the combination of high-resolution, real-time imaging 'real-time' imaging Visualization of a dynamic process µsecs after occurring, which requires rapid information processing–ie, as the process occurs, as in 'B' mode ultrasound , in vivo detection and analysis, reasonable cost, ease-of-use, portability and no negative biological effects. More information on VisualSonics can be found at www.visualsonics.com. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion